RALA

Ras-related protein Ral-A · P11233 · RALA on Sugi Atlas →

0 patent compounds predicted against RALA, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RALA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). PHASE3WITHDRAWN
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation PHASE2COMPLETED
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS PHASE2RECRUITING
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy PHASE2COMPLETED
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma PHASE2UNKNOWN
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors PHASE1RECRUITING
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas PHASE1COMPLETED
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients nanCOMPLETED
Characterisation of Gene Variants in the Angiogenic Pathway nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RALA binder may also engage these)

ProteinNameSimilarity
P63322 1.000 P63322 →
P63321 1.000 P63321 →
P63320 1.000 P63320 →
Q9YH09 0.980 Q9YH09 →
P22124 0.979 P22124 →
P36860 0.978 P36860 →
Q5R4B8 0.977 Q5R4B8 →
P11234 0.977 P11234 →
P48555 0.976 P48555 →
Q9JIW9 0.975 Q9JIW9 →
Q4R379 0.975 Q4R379 →
Q6IP71 0.959 Q6IP71 →
Q95KD9 0.920 Q95KD9 →
PRKG1 cGMP-dependent protein kinase 1 0.915 landscape →
P00516 0.915 P00516 →
Q5PR73 0.915 Q5PR73 →
Q96HU8 0.915 Q96HU8 →
RHEB GTP-binding protein Rheb 0.913 landscape →
O77676 0.912 O77676 →
Q56JV3 0.910 Q56JV3 →
Q969Q5 0.910 Q969Q5 →
Q5ZM91 0.909 Q5ZM91 →
P07802 0.909 P07802 →
P81377 0.908 P81377 →
Q5R6S2 0.908 Q5R6S2 →
Q5REL1 0.908 Q5REL1 →
P10644 0.908 P10644 →
P35290 0.908 P35290 →
P0C605 0.907 P0C605 →
P00514 0.907 P00514 →